Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Dyslipidemia

Dyslipidemia is a disorder of lipoprotein metabolism expressed through quantitative or qualitative changes in plasma lipids. It may present as increased LDL-C, triglycerides, non-HDL cholesterol, or lipoprotein(a), reduced HDL-C, or combinations of these findings. The term identifies a clinical and biochemical problem, not a single disease with a uniform cause and course. A complete diagnosis must specify which particles are increased, why they are elevated, how long the abnormality has persisted, and what consequences it has for the individual.

An initial distinction concerns the relationship between a laboratory value and a treatment target. A laboratory's reference interval does not necessarily correspond to the desirable concentration for a patient who has already had a myocardial infarction or has high cardiovascular risk. Conversely, increased total cholesterol predominantly attributable to HDL does not have the same significance as increased LDL. Interpretation therefore requires the full lipid profile, clinical context, and, where necessary, additional measures of lipoprotein burden.

Atherogenic dyslipidemias are modifiable determinants of cardiovascular disease, but some forms have additional implications: extreme accumulation of triglyceride-rich lipoproteins can cause pancreatitis, while rare lipid transport disorders may be accompanied by hepatic, neurological, or hematological abnormalities. This monograph mainly addresses conditions associated with excess atherogenic particles and hypertriglyceridemia, while keeping the characterization of dyslipidemia separate from diagnosis of any resulting complications.

Population prevalence varies considerably with the definition used, age, metabolic conditions, and medication use. An estimate based on total cholesterol does not describe the same population as one based on LDL-C, triglycerides, or apoB. Including people already receiving treatment also changes the meaning of prevalence: a currently normal value does not eliminate a diagnosis controlled by medication. This variability makes it uninformative to assign dyslipidemia a single percentage without specifying the population and criteria.

Etiology, classification, and pathogenesis

The most straightforward classification is phenotypic: predominantly LDL hypercholesterolemia, hypertriglyceridemia, mixed dyslipidemia, low HDL-C, and elevated Lp(a). The historical Fredrickson classification describes increases in chylomicrons, LDL, VLDL, or remnant particles, distinguishing types I, IIa, IIb, III, IV, and V. It retains descriptive value but does not necessarily identify the molecular defect, does not adequately represent all HDL or Lp(a) abnormalities, and may change in the same person as metabolic conditions vary. It should therefore not be treated as synonymous with a genetic diagnosis.

Monogenic forms result from alterations in proteins essential for lipoprotein production, processing, or removal. Defects in the LDL receptor pathway may cause hypercholesterolemia from childhood; profound abnormalities of lipoprotein lipase or proteins required for its function may cause chylomicronemia. Other conditions affect remnant recognition, sterol transport, or lysosomal hydrolysis of cholesterol esters. The rarity of these diseases does not warrant indiscriminate molecular screening, but it makes recognition of their clinical clues essential when present.

In clinical practice, polygenic and multifactorial forms predominate. Numerous variants influence baseline lipid levels and responses to diet, adiposity, and hormones; environmental factors may amplify an existing predisposition. Familial clustering is not equivalent to monogenic inheritance: several members of a family may share small-effect genes and habits, while a monogenic disorder may be present even when family history is incomplete or apparently negative.

Secondary causes must be investigated before permanently classifying a presentation as primary. Hypothyroidism reduces LDL clearance and may also raise triglycerides. Poorly controlled diabetes increases substrate availability for hepatic triglyceride synthesis and can impair the removal of triglyceride-rich lipoproteins. Nephrotic syndrome is associated with changes in lipoprotein production and catabolism, often with marked hypercholesterolemia; chronic kidney disease without nephrotic syndrome primarily promotes remnant and HDL abnormalities. In cholestasis, increased cholesterol may also result from lipoprotein X, an abnormal particle distinct from atherogenic LDL.

Medication history is part of etiological assessment. Glucocorticoids, retinoids, certain antipsychotics, oral estrogens, some immunosuppressants, and antiretroviral therapies can affect the lipid profile through different mechanisms. Their effects depend on the agent, dose, duration, and individual susceptibility. Any substitution must be agreed with the clinician managing the underlying disease: independently stopping necessary treatment can cause more harm than the lipid abnormality itself.

Normal metabolism connects the exogenous pathway, which distributes lipids absorbed from the intestine via apoB48-containing chylomicrons, to the endogenous pathway, in which the liver secretes apoB100-containing VLDL. Lipoprotein lipase hydrolyzes triglycerides and makes fatty acids available to tissues. Remnants are cleared by the liver or further transformed; some VLDL particles progress through IDL to LDL. Defects at different steps may produce similar laboratory findings but require different interpretations and treatments.

With insulin resistance, increased fatty acid flux from adipose tissue, hepatic lipogenesis, and altered catabolism promote VLDL accumulation. Lipid exchange and subsequent lipase activity modify LDL and HDL, producing smaller LDL particles relatively poor in cholesterol and increased catabolism of some HDL particles. LDL-C may therefore not be particularly high despite an increased number of atherogenic particles. This explains why the typical profile of diabetes or visceral adiposity cannot be judged on LDL cholesterol alone.

Arterial retention of apoB-containing particles is the main link to atherosclerosis. Cholesterol concentration measures the lipid load carried, whereas apoB more directly reflects particle number. The two measurements may diverge, and discordance is not inherently an error: it may indicate different lipoprotein composition. For triglycerides, it is also necessary to distinguish the accumulation of atherogenic remnants from massive chylomicronemia; the size of chylomicrons limits entry into the arterial wall, and their predominant risk is often pancreatic.

Hypertriglyceridemic pancreatitis is understood through interactions among chylomicronemia, microcirculatory abnormalities, and local release of potentially toxic fatty acids. Risk increases with severity and persistence of hypertriglyceridemia, without an absolute biological threshold separating safety from danger. Moreover, pharmacologically reducing a biomarker does not by itself establish that every intervention on that biomarker prevents the same complication: mechanism, treated population, and trial outcomes remain essential.

HDL particles participate in cholesterol acquisition from cells, transport, and exchange with other lipoproteins, but encompass particles with diverse properties. Reduced HDL-C in an insulin-resistant profile may reflect changes in composition and catabolism without identifying an isolated reverse cholesterol transport defect. Extremely low levels, particularly when disproportionate to triglycerides and associated with systemic findings, raise a distinct specialist diagnostic question that may involve defects in apoA-I, ABCA1, or LCAT. Even in this setting, the biochemical phenotype alone cannot establish risk or cause.

Clinical manifestations, medical history, and physical examination

The usual presentation is an incidental finding during routine laboratory tests. Headache, tiredness, dizziness, or a sensation of heaviness are not specific symptoms of dyslipidemia. Absence of direct manifestations does not mean the condition is benign: atherosclerosis may progress for a long time before ischemia or an acute event occurs. When a patient reports chest pain, neurological deficits, or severe abdominal pain, assessment for a possible complication must proceed according to its urgency, without waiting for the lipid workup to be completed.

Personal history establishes age at first detection, pretreatment values, triglyceride fluctuations, treatments, and responses. Previous coronary syndromes, ischemic stroke, peripheral artery disease, pancreatitis, and liver disease are important. Alcohol consumption, weight changes, dietary composition, physical activity, pregnancy, and hormonal transitions should be clarified. An extremely high value during diabetic decompensation should not automatically be assumed to represent the usual level, but it remains clinically important and requires management and reassessment.

Family history includes premature cardiovascular events, very high lipid values, recurrent pancreatitis, and previously documented diagnoses. For premature events, it is useful to record actual age and degree of kinship, rather than a nonspecific “heart problem.” Medical records and test reports, when available, improve accuracy. A negative family history may reflect a small family, limited knowledge of relatives, or effective preventive treatment and does not rule out a hereditary cause.

Physical examination assesses tendon xanthomas, particularly on the Achilles tendons and hand extensor tendons, which are consistent with substantial lipid exposure and possible inherited forms. Eruptive xanthomas, small yellowish lesions on an erythematous base, suggest severe hypertriglyceridemia; palmar xanthomas may suggest remnant accumulation. Xanthelasmas and corneal arcus are less specific, particularly in older adults. Lipemia retinalis is a finding of extreme hypertriglyceridemia, not an expected manifestation of common forms.

General assessment includes central adiposity, blood pressure, peripheral pulses, signs of hypothyroidism, edema, hepatomegaly, and findings compatible with lipodystrophy. Loss of subcutaneous adipose tissue in some areas, marked insulin resistance, and high triglycerides may suggest defective adipose storage capacity rather than simple excess caloric intake. Physical examination does not quantify plaque burden but guides investigations and identifies conditions that modify the significance of laboratory results.

Investigations and biochemical diagnosis

The initial test is a complete lipid profile. Total cholesterol, HDL-C, and triglycerides are measured; LDL-C may be calculated or determined by a direct assay. Non-HDL cholesterol is obtained by subtracting HDL-C from total cholesterol, without another blood draw. It is necessary to know whether sampling was fasting, the method used for LDL-C, and any potential interference. An unexpected result should be assessed with the laboratory, rather than interpreted as a definitive diagnosis regardless of its plausibility.

Fasting is not mandatory for every lipid assessment: a nonfasting sample often provides valid screening and reflects the state in which people spend most of the day. Repeating the test in a fasting state is useful, however, when triglycerides are markedly elevated, a genetic dyslipidemia with chylomicronemia is suspected, or the result may affect treatment decisions. The EAS/EFLM consensus suggests considering a repeat fasting test when nonfasting triglycerides exceed 440 mg/dL. Assessment of a symptomatic patient should not be delayed to obtain ideal analytical conditions.

The Friedewald formula, expressed in mg/dL, subtracts HDL-C and triglycerides divided by five from total cholesterol. It assumes a relatively stable ratio of triglycerides to cholesterol in VLDL; it becomes unreliable when this relationship changes and must not be used at triglyceride levels of 400 mg/dL or above. It may also underestimate LDL-C at lower concentrations, particularly when actual LDL-C is low. More recent equations improve estimation in certain circumstances but must be used within their validated ranges; a direct assay is not automatically free of problems in extreme dyslipidemias.

Non-HDL-C includes cholesterol carried by LDL, IDL, VLDL, remnants, and Lp(a). It is particularly informative when triglycerides are elevated because it does not restrict assessment to LDL. ApoB helps identify an increased particle number despite apparently satisfactory LDL-C, especially in diabetes, obesity, and mixed profiles. Remnant cholesterol calculated by subtraction can provide an indication but inherits errors from its component measurements and is not a direct measurement of a single homogeneous class.

Descriptive thresholds must be distinguished from treatment indications. Fasting triglycerides of 150 mg/dL and nonfasting triglycerides of 175 mg/dL are commonly used reference points indicating elevation; however, 180 mg/dL has a very different significance from 1,500 mg/dL. HDL-C below 40 mg/dL in men or 50 mg/dL in women contributes to the metabolic phenotype but does not define a pharmacological target to be reached by raising HDL. For LDL-C, the desirable concentration mainly depends on risk rather than a single normal range applicable to everyone.

Lp(a) is generally measured at least once in adulthood to identify an inherited determinant inadequately represented by the routine lipid panel. Its concentration must not be converted from mg/dL to nmol/L using a fixed factor, because apolipoprotein(a) mass varies between individuals. Kidney disease, inflammatory conditions, and specific clinical settings may require cautious interpretation or repeat assessment. Elevated Lp(a) cannot be inferred from LDL-C alone and is not excluded by normal total cholesterol.

To confirm persistence of the abnormality, at least two measurements separated by an interval consistent with clinical stability are often appropriate. This principle must not create therapeutic inertia after a cardiovascular event or in the presence of extreme values. Acute illness, recent dietary changes, dehydration, pregnancy, and newly started medications may influence results. An early lipid profile in acute coronary syndrome is useful because cholesterol may fall over the following days and no longer represent usual exposure.

Tests for associated conditions include, when indicated, blood glucose and glycated hemoglobin, TSH with FT4 if appropriate, creatinine and estimated glomerular filtration rate, albuminuria or proteinuria assessment, and liver biochemistry including cholestatic markers. The combination of marked hypercholesterolemia, edema, and proteinuria suggests nephrotic syndrome; a cholestatic profile with very high cholesterol and relatively little elevation in apoB suggests a possible lipoprotein X component. Investigations should answer specific questions and be reassessed after treatment of the cause.

The differential diagnosis also includes analytical interference and rare conditions. Falsely elevated triglycerides may occur in particular circumstances involving free glycerol; highly lipemic samples can interfere with other assays. Early xanthomas are not exclusive to familial hypercholesterolemia: sitosterolemia and other diseases require different tests when suggested by the context. The aim is not to label every abnormality as genetic but to prevent an incongruent result from leading to inappropriate treatment.

Etiological assessment, risk, and further investigations

Once the phenotype is confirmed, the next step is to determine whether it represents a predominantly acquired disorder, a common predisposition, or a specific inherited disease. Persistently very high LDL-C, early onset, xanthomas, and familial clustering warrant assessment for familial hypercholesterolemia. Extremely high triglycerides from childhood, recurrent pancreatitis, and poor response to conventional measures instead suggest a possible profound defect in the lipolytic pathway. Genetic panels should be selected according to these suspicions and accompanied by clinical interpretation of variants.

A variant of uncertain significance does not constitute diagnostic confirmation, while a negative test does not exclude polygenic predisposition or every hereditary cause. When a pathogenic variant consistent with the phenotype is identified, testing family members may allow early diagnosis. If no informative variant is available, lipid screening of relatives remains useful in families with a marked phenotype. Testing should add information that can change prevention, counseling, or treatment, not serve as a compulsory step before starting indicated therapy.

When dysbetalipoproteinemia is suspected, cholesterol-rich remnant accumulation, palmar xanthomas, and a mixed profile require characterization distinct from isolated LDL hypercholesterolemia. ApoB and lipoprotein distribution can guide assessment, while APOE analysis contributes in appropriate cases. The most common predisposing genotype is insufficient to diagnose clinically expressed disease: additional factors often further impair remnant clearance. This example shows why diagnosis must integrate genetics and phenotype rather than substitute one for the other.

Vascular risk stratification distinguishes primary from secondary prevention and integrates age, blood pressure, smoking, diabetes, kidney function, and family history. Models validated for the population and age group are used in apparently healthy adults; they should not be applied indiscriminately to severe genetic disorders or known atherosclerotic disease. A value measured during treatment should not be used to reclassify the patient as though their lifelong untreated exposure had always been naturally low.

Selective imaging for subclinical disease may contribute when the preventive decision remains uncertain and the result can change it. Demonstrating plaque is not required to diagnose dyslipidemia, and routinely ordering exercise tests, coronary CT angiography, or multisite ultrasound for every asymptomatic patient is inappropriate. Symptoms or signs of ischemia prompt a separate diagnostic pathway. LDL subclass quantification, particle size measurements, and extended panels do not replace standard parameters and are generally unnecessary in routine management.

Treatment and monitoring

The first principle is to treat a modifiable cause without losing sight of immediate risk. Correcting hypothyroidism may substantially change the lipid profile; controlling severe hyperglycemia may rapidly reduce triglycerides. However, residual dyslipidemia must be reassessed and not assumed to have resolved simply because the associated disease has improved. In patients with cardiovascular disease or another strong indication, etiological treatment and prevention may require coordinated rather than prolonged sequential approaches.

Nutritional intervention depends on the phenotype. For elevated LDL, replacing saturated with unsaturated fats, increasing fiber, and adopting an overall cardioprotective dietary pattern are central. With hypertriglyceridemia, reducing excess energy intake, sugars, and alcohol becomes especially important. Severe chylomicronemia requires more restrictive fat advice and nutritional supervision to maintain dietary adequacy. It is therefore incorrect to propose the same diet for every lipid abnormality.

Physical activity, weight reduction when indicated, and smoking cessation act on different components of risk. Success is not measured solely by a change in total cholesterol: triglycerides, blood pressure, insulin sensitivity, and functional capacity may improve even when LDL-C changes little. These interventions continue alongside medication but must not become prerequisites that delay necessary lipid lowering for months in a high-risk patient.

Reducing LDL-C remains the main pharmacological target for preventing atherosclerotic events. European targets depend on risk category: in very-high-risk patients, the aim is below 55 mg/dL together with at least a 50% reduction from baseline; at high risk, the corresponding target is below 70 mg/dL with a similar percentage reduction. At moderate risk, the reference is below 100 mg/dL, while below 116 mg/dL may be considered at low risk. These values guide treatment strategies and are not universal diagnostic thresholds for dyslipidemia.

Statins lower hepatic cholesterol synthesis and promote LDL receptor-mediated clearance. Intensity is chosen according to the gap from the target and tolerability; when monotherapy cannot achieve the needed reduction, early combination with ezetimibe or other treatments may be planned. Anti-PCSK9 antibodies, bempedoic acid, and inclisiran expand treatment options but differ in mechanism, administration, and clinical event evidence. Hypercholesterolemia requires an approach proportionate to both concentration and cumulative exposure.

When triglycerides are elevated but not in a range where pancreatic risk predominates, cardiovascular risk management is not confined to normalizing them. PROMINENT showed that triglyceride lowering with pemafibrate did not reduce cardiovascular events in the population studied. Icosapent ethyl, by contrast, demonstrated benefit in selected patients already on statins; its indication requires assessment of risk, triglycerides, and possible adverse effects, including atrial fibrillation and bleeding. These findings do not justify indiscriminate use of mixed omega-3 formulations or supplements.

With severely elevated triglycerides, particularly around 1,000 mg/dL or higher, eliminating precipitating factors and preventing pancreatitis take priority. Even above 500 mg/dL, specific interventions and the risk of further increases must be considered. Fibrates and prescription omega-3 preparations may be used according to context; particular genetic forms require a lipid specialist center. Severe abdominal pain with suspected pancreatitis requires urgent care, not merely outpatient dietary adjustment.

Choosing a fibrate requires attention to kidney function and drug combinations. When a statin combination is necessary, fenofibrate is generally preferable to gemfibrozil because of a lower risk of muscle-related interactions, while still requiring appropriate surveillance. Triglyceride reduction achieved through control of the cause does not remove the need to reassess LDL-C and non-HDL cholesterol: a different priority target may become apparent once the most severe phase has resolved. In acute pancreatitis, insulin infusion and plasmapheresis are not interventions to apply automatically to every patient; indications and expected benefits depend on the clinical situation, including the presence of hyperglycemia.

Low HDL-C is not treated by prescribing a drug solely to raise it. Similarly, elevated Lp(a) calls for attention to overall risk and other modifiable exposures, without assuming that any numerical reduction has already demonstrated a specific clinical benefit. Non-HDL cholesterol and apoB targets can complement LDL-C targets in discordant profiles; they are most useful when they help avoid underestimating atherogenic burden, not when they add tests without changing decisions.

Response assessment is generally performed within several weeks of starting or changing treatment, often at 4–12 weeks, or sooner when circumstances require. Subsequent frequency depends on stability, risk, and adherence. Before intensification, actual use, doses, interactions, and changes in secondary causes are reviewed. Transaminases are assessed at baseline and rechecked according to the medication and context; creatine kinase does not require indiscriminate repeated testing in an asymptomatic patient but becomes important with muscle symptoms or predisposing factors.

Muscle symptoms occurring during statin therapy require a timeline, investigation of strenuous exercise, hypothyroidism, and interactions, and assessment of any response to a supervised withdrawal and rechallenge. Intolerance may be partial, allowing a lower dose or another statin, or complete. It should not be defined on the basis of a single uncharacterized episode. In high-risk patients, investigation of tolerability should be accompanied by an effective alternative strategy, avoiding prolonged periods without lipid protection.

During pregnancy, childhood, advanced kidney failure, or substantial frailty, treatment requires specific expertise and precautions. Pregnancy physiologically alters lipid levels and limits routine use of many lipid-lowering agents; in severe genetic forms, maternal and fetal risks should be discussed by a dedicated multidisciplinary team. Treatment in children is not an automatic application of adult regimens. In older adults, autonomy, prognosis, interactions, and agreed goals matter in addition to chronological age.

Prognosis and complications

Vascular prognosis is determined by exposure over time and its interaction with other causal factors. Sustained reduction of atherogenic particles lowers the probability of events but does not immediately erase accumulated damage. Prevention is therefore more effective when it starts before a complication and is maintained. Stopping effective treatment generally allows the phenotype to reappear, because treatment-induced normalization is not the same as curing the predisposition.

Atherosclerotic complications include myocardial infarction, ischemic stroke, peripheral artery disease, and polyvascular disease. The relative contribution of dyslipidemia varies among vascular territories and combines with hypertension, smoking, diabetes, and thrombotic factors. Consequences may include heart failure, limb ischemia, the need for revascularization, and disability. Lipid control remains necessary after a successful procedure, which treats a lesion or its consequences but does not eliminate the systemic cause.

Recurrent pancreatitis can impair pancreatic function and quality of life in chylomicronemia, so it requires specific prevention rather than merely an estimate of coronary risk. Xanthomas and other extravascular deposits may reflect the duration and severity of exposure, but their regression is not the sole measure of success. Finally, treatment adverse effects must be distinguished from complications of dyslipidemia: appropriate monitoring and shared decisions preserve benefit without dismissing symptoms.

References
  1. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111–188.
  2. Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378.
  3. Borén J et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2020;41(24):2313–2330.
  4. Ginsberg HN et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. European Heart Journal. 2021;42(47):4791–4806.
  5. Newman CB et al. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2020;105(12):3613–3682.
  6. Nordestgaard BG et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal. 2016;37(25):1944–1958.
  7. Langlois MR et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry. 2018;64(7):1006–1033.
  8. Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925–3946.
  9. Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–3337.
  10. Nordestgaard BG et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal. 2013;34(45):3478–3490.
  11. Cuchel M et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. European Heart Journal. 2023;44(25):2277–2291.
  12. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet. 2010;376(9753):1670–1681.
  13. Cannon CP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine. 2015;372(25):2387–2397.
  14. Sabatine MS et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine. 2017;376(18):1713–1722.
  15. Nissen SE et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. The New England Journal of Medicine. 2023;388(15):1353–1364.
  16. Ray KK et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England Journal of Medicine. 2020;382(16):1507–1519.
  17. Das Pradhan A et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. The New England Journal of Medicine. 2022;387(21):1923–1934.
  18. Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine. 2019;380(1):11–22.
  19. Stroes ES et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015;36(17):1012–1022.
  20. Cheeley MK et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. Journal of Clinical Lipidology. 2022;16(4):361–375.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.